Despite improvements in clinical outcomes following acute myocardial infarction, mortality
remains high, especially in patients with severely reduced left ventricular ejection fraction …

Anxiety or depression after percutaneous coronary intervention (PCI) is one of the key
clinical problems in cardiology that need to be solved urgently. Brain-derived neurotrophic …

Background Patients treated with drug-coated balloons (DCB) have the theoretical
advantage of adopting a low-intensity antiplatelet regimen due to the absence of struts and …

Background East Asians (EAs), compared to white Caucasians (W), have a lower risk of
ischemic heart disease and a higher risk of bleeding with antithrombotic medications. The …

The principal goals of dual antiplatelet therapy (DAPT) after percutaneous coronary
intervention (PCI) are prevention of stent thrombosis and, in those treated for acute coronary …

Background: In patients undergoing percutaneous coronary intervention (PCI), the use of
anti-inflammatory therapy with colchicine is associated with a reduction of recurrent ischemic …

Background Impaired endogenous fibrinolysis is adverse cardiovascular risk factor in acute
coronary syndrome (ACS) patients. Addition of very low dose rivaroxaban (VLDR) to dual …

Aim: Implementation of CYP2C19 point-of-care (POC) pharmacogenetic (PGx) testing with
personalized treatment recommendations. Methods: POC CYP2C19 genotyping plus expert …

The incidence of cardiogenic shock (CS) is increasing 1–3 and continues to carry a very
high in-hospital mortality rate of 40–50%. 4, 5 Patients often present late and manifest …

Despite a relentless effort to shift the paradigm in antiplatelet strategies towards a reduction
of bleeding without any trade-off in thrombotic events—known as bleeding reduction …